Furthermore, previous studies have reported that the STING agonist (c-di-GMP) can be encapsulated by lipid nanoparticles (LNP), resulting in the formation of STING-LNP, which was successfully delivered to the cytoplasm, thereby successful induction of anti-tumor immunity through the activation of CD8+ T and NK cells [65, 66]. The gene discussed is CD8A; the disease is neoplasm.